Prostatic Hyperplasia Treatment and Cancer Prevention

Manchanda Medical Clinic

Status and phase: Unknown; Early Phase 1

Conditions: Prostatic Hyperplasia

Treatments: Drug: papaverine; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03064282

Tawar - 2

Details and patient eligibility

About

Treatment of patients with prostatic hyperplasia with topical papaverine.

Full description

Patients with obstructive voiding and high PSA to be studied for the regression of symptoms and declining PSA.

Enrollment: 40 estimated patients

Sex: Male

Ages: 50 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patients with symptoms e.g. obstructive voiding, hyperplasia and high PSA

Exclusion criteria

• patients on chemotherapy
• abnormal lab values e.g. liver function, GFR and CAD

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Drug free base as placebo

Treatment:

Other: Placebo

group two- papaverine arm

Experimental group

Description:

papaverine in a suitable base

Treatment:

Drug: papaverine